TAG prepared these remarks to deliver at United Nations High-Level Meetings (UN HLMs) on tuberculosis (TB), universal health coverage (UHC), and pandemic prevention, preparedness, and response (PPR). While we welcome public reaffirmation of commitments to end TB, we urge member…
TAG is a longstanding champion of the human right to science, which we believe entitles everyone, everywhere to benefit from the best available tools to end HIV, TB, and HCV.
We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.
TAG prepared these remarks to deliver at multistakeholder hearings on health held on May 8 and 9, 2023, at the United Nations Headquarters in New York City.
This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.
A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.
At the first of these two public hearings TAG submitted the following statement with six reasons why the new international instrument must explicitly acknowledge the right to science as a central guiding framework.
TAG’s staff and board of directors are filled with grief at the premature death of Dr. Paul Farmer, who illuminated and changed our world with his combination of passion, intelligence, solidarity with the poor, and determined will for social justice.
On February 9, TAG submitted this testimony to the Office of the High Commission for Human Rights (OHCHR) to inform its upcoming report to the Human Rights Council (HRC) on 'human rights in the context of HIV/AIDS' (HRC resolution 47/17).
Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.